Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?

被引:10
|
作者
Kuang, Ze-Min [1 ]
机构
[1] Capital Med Univ, Dept Hypertens, Beijing Anzhen Hosp, Beijing 100029, Peoples R China
关键词
CARDIOVASCULAR RISK-FACTORS; SYSTOLIC BLOOD-PRESSURE; SERUM-CHOLESTEROL; STATIN USE; ALZHEIMERS-DISEASE; DEMENTIA; DECLINE; ASSOCIATION; MIDLIFE; HYPERTENSION;
D O I
10.1155/2020/1484357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive decline or development of dementia. To provide a reference for clinical treatment, we analyzed the potential mechanisms of cognitive dysfunction induced by hypertension and hyperlipidemia, the clinical research and controversy of antihypertensive and lipid-lowering therapies on cognitive function, and the clinical value of combined antihypertensive and lipid-lowering therapy. It is currently believed that hypertension and elevated blood cholesterol levels in middle-aged people may be related to cognitive impairment or dementia in the elderly. Some studies suggest that intensive antihypertensive or lipid-lowering therapies are better than standard antihypertensive or lipid-lowering therapy, yet further tests are needed to confirm their effects on cognitive function. Actively controlling potential risk factors from middle age may be important for Alzheimer's disease (AD) prevention.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Effect of Semaglutide 2.4 mg on Use of Antihypertensive and Lipid-lowering Treatment in STEP Trials
    Knight, Michael
    Adelborg, Kasper
    Clements, Jennifer
    Iversen, Aske Thorn
    Laursen, Peter
    Tchang, Beverly
    Traina, Andrea
    OBESITY, 2023, 31 : 250 - 250
  • [22] Comparative effects of lipid-lowering therapies
    Davidson, MH
    Toth, PP
    PROGRESS IN CARDIOVASCULAR DISEASES, 2004, 47 (02) : 73 - 104
  • [23] Personalize and Optimize Lipid-Lowering Therapies
    Weingaertner, Oliver
    Luetjohann, Dieter
    Elsaesser, Albrecht
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (03) : 325 - 326
  • [24] Pharmacogenetics of Lipid-lowering Therapies.
    Ordovas J.M.
    Shen H.
    Current Atherosclerosis Reports, 2002, 4 (3) : 183 - 192
  • [25] Lipid-lowering drug therapies: the evidence
    Packard, C
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2000, 59 (03) : 423 - 424
  • [26] Lipid-lowering therapies: Better together
    Banach, Maciej
    Penson, Peter E.
    ATHEROSCLEROSIS, 2021, 320 : 86 - 88
  • [27] Adherence with concomitant antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Battleman, DS
    Schwartz, S
    CIRCULATION, 2003, 108 (17) : 756 - 757
  • [28] Predictors of adherence with antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Collins, SR
    Battleman, DS
    Schwartz, JS
    ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1147 - 1152
  • [29] Adherence With Lipid-Lowering, Antihypertensive, and Diabetes Medications
    Davis, James W.
    Fujimoto, Ronald Y.
    Chan, Henry
    Juarez, Deborah T.
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2011, 3 (03) : 165 - 171
  • [30] Plaque hypertension lipid-lowering Italian study (PHYLLIS): Echoreflectivity study on arterial carotid wall changes during longterm antihypertensive and lipid-lowering therapies
    Ciulla, M. M.
    Paliotti, R.
    Annoni, G.
    Veglia, F.
    Magrini, F.
    Zanchetti, A.
    JOURNAL OF HYPERTENSION, 2006, 24 : 364 - 365